Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

141 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.
Wylie AA, Schoepfer J, Jahnke W, Cowan-Jacob SW, Loo A, Furet P, Marzinzik AL, Pelle X, Donovan J, Zhu W, Buonamici S, Hassan AQ, Lombardo F, Iyer V, Palmer M, Berellini G, Dodd S, Thohan S, Bitter H, Branford S, Ross DM, Hughes TP, Petruzzelli L, Vanasse KG, Warmuth M, Hofmann F, Keen NJ, Sellers WR. Wylie AA, et al. Among authors: furet p. Nature. 2017 Mar 30;543(7647):733-737. doi: 10.1038/nature21702. Epub 2017 Mar 22. Nature. 2017. PMID: 28329763
Selective GRB2 SH2 inhibitors as anti-Ras therapy.
Gay B, Suarez S, Caravatti G, Furet P, Meyer T, Schoepfer J. Gay B, et al. Among authors: furet p. Int J Cancer. 1999 Oct 8;83(2):235-41. doi: 10.1002/(sici)1097-0215(19991008)83:2<235::aid-ijc15>3.0.co;2-b. Int J Cancer. 1999. PMID: 10471533 Free article.
Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.
Fabbro D, Ruetz S, Buchdunger E, Cowan-Jacob SW, Fendrich G, Liebetanz J, Mestan J, O'Reilly T, Traxler P, Chaudhuri B, Fretz H, Zimmermann J, Meyer T, Caravatti G, Furet P, Manley PW. Fabbro D, et al. Among authors: furet p. Pharmacol Ther. 2002 Feb-Mar;93(2-3):79-98. doi: 10.1016/s0163-7258(02)00179-1. Pharmacol Ther. 2002. PMID: 12191602 Review.
Imatinib: a selective tyrosine kinase inhibitor.
Manley PW, Cowan-Jacob SW, Buchdunger E, Fabbro D, Fendrich G, Furet P, Meyer T, Zimmermann J. Manley PW, et al. Among authors: furet p. Eur J Cancer. 2002 Sep;38 Suppl 5:S19-27. doi: 10.1016/s0959-8049(02)80599-8. Eur J Cancer. 2002. PMID: 12528769 Review.
141 results